Laurence Zitvogel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7945198/publications.pdf

Version: 2024-02-01

429 papers	99,806 citations	435 131 h-index	250 301 g-index
452 all docs	452 docs citations	452 times ranked	81059 citing authors

#	Article	IF	Citations
1	Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2002, 2, 569-579.	22.7	4,401
2	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
3	Gut microbiome influences efficacy of PD-1â€“based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	12.6	3,689
4	Toll-like receptor 4â€“dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine, 2007, 13, 1050-1059.	30.7	2,657
5	Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine, 2007, 13, 54-61.	30.7	2,580
6	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015, 350, 1079-1084.	12.6	2,539
7	Immunogenic Cell Death in Cancer Therapy. Annual Review of Immunology, 2013, 31, 51-72.	21.8	2,489
8	Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science, 2011, 331, 44-49.	12.6	2,234
9	Immunogenic cell death in cancer and infectious disease. Nature Reviews Immunology, 2017, 17, 97-111.	22.7	2,000
10	Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nature Medicine, 1998, 4, 594-600.	30.7	1,908
11	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1Î²â€“dependent adaptive immunity against tumors. Nature Medicine, 2009, 15, 1170-1178.	30.7	1,614
12	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	27.6	1,590
13	The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. Science, 2013, 342, 971-976.	12.6	1,580
14	Antigen Presentation and T Cell Stimulation by Dendritic Cells. Annual Review of Immunology, 2002, 20, 621-667.	21.8	1,577
15	Immunological aspects of cancer chemotherapy. Nature Reviews Immunology, 2008, 8, 59-73.	22.7	1,374
16	Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature Medicine, 2001, 7, 297-303.	30.7	1,362
17	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. Journal of Experimental Medicine, 2005, 202, 1691-1701.	8.5	1,224
18	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell, 2015, 28, 690-714.	16.8	1,205

#	Article	IF	Citations
19	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. Science, 2011, 334, 1573-1577.	12.6	1,159
20	Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Reviews Immunology, 2006, 6, 715-727.	22.7	1,108
21	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 2007, 56, 641-648.	4.2	1,104
22	Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Medicine, 1999, 5, 405-411.	30.7	984
23	Immunogenic and tolerogenic cell death. Nature Reviews Immunology, 2009, 9, 353-363.	22.7	970
24	Molecular Characterization of Dendritic Cell-Derived Exosomes. Journal of Cell Biology, 1999, 147, 599-610.	5.2	950
25	Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?. Science, 2013, 339, 286-291.	12.6	943
26	Type I interferons in anticancer immunity. Nature Reviews Immunology, 2015, 15, 405-414.	22.7	929
27	Cancer cellâ€“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	30.7	823
28	Malignant effusions and immunogenic tumour-derived exosomes. Lancet, The, 2002, 360, 295-305.	13.7	822
29	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factorâ€“Î²â€“dependent manner. Journal of Experimental Medicine, 2005, 202, 1075-1085.	8.5	806
30	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269.	14.3	797
31	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity, 2016, 44, 343-354.	14.3	767
32	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. Journal of Clinical Investigation, 2010, 120, 457-71.	8.2	761
33	Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. Immunity, 2013, 39, 74-88.	14.3	739
34	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews Clinical Oncology, 2020, 17, 725-741.	27.6	701
35	Consensus guidelines for the detection of immunogenic cell death. OncoImmunology, 2014, 3, e955691.	4.6	686
36	Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO Journal, 2009, 28, 578-590.	7.8	683

#	Article	IF	Citations
37	Tumor cells convert immature myeloid dendritic cells into TGF-Î²â€“secreting cells inducing CD4+CD25+ regulatory T cell proliferation. Journal of Experimental Medicine, 2005, 202, 919-929.	8.5	676
38	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 2020, 182, 1401-1418.e18.	28.9	663
39	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. Immunity, 2016, 45, 931-943.	14.3	645
40	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
41	Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews Clinical Oncology, 2011, 8, 151-160.	27.6	592
42	The secret ally: immunostimulation by anticancer drugs. Nature Reviews Drug Discovery, 2012, 11, 215-233.	46.4	591
43	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. Immunity, 2013, 38, 729-741.	14.3	572
44	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology, 2016, 5, e1071008.	4.6	545
45	Inflammasomes in carcinogenesis and anticancer immune responses. Nature Immunology, 2012, 13, 343-351.	14.5	525
46	The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science, 2018, 359, 1366-1370.	12.6	525
47	The anticancer immune response: indispensable for therapeutic success?. Journal of Clinical Investigation, 2008, 118, 1991-2001.	8.2	520
48	The microbiome and human cancer. Science, 2021, 371, .	12.6	506
49	Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nature Immunology, 2017, 18, 1004-1015.	14.5	504
50	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunological Reviews, 2007, 220, 47-59.	6.0	491
51	Decoding Cell Death Signals in Inflammation and Immunity. Cell, 2010, 140, 798-804.	28.9	482
52	Immunogenic cell stress and death. Nature Immunology, 2022, 23, 487-500.	14.5	434
53	Dendritic cellâ€“derived exosomes for cancer therapy. Journal of Clinical Investigation, 2016, 126, 1224-1232.	8.2	427
54	Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells. Journal of Immunology, 2004, 172, 2126-2136.	0.8	424

#	Article	IF	Citations
55	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer Cell, 2016, 30, 147-160.	16.8	410
56	Anticancer effects of the microbiome and its products. Nature Reviews Microbiology, 2017, 15, 465-478.	28.6	399
57	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
58	The gut microbiota influences anticancer immunosurveillance and general health. Nature Reviews Clinical Oncology, 2018, 15, 382-396.	27.6	389
59	A novel dendritic cell subset involved in tumor immunosurveillance. Nature Medicine, 2006, 12, 214-219.	30.7	377
60	Extracellular vesicles: masters of intercellular communication and potential clinical interventions. Journal of Clinical Investigation, 2016, 126, 1139-1143.	8.2	375
61	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell, 2016, 29, 587-601.	16.8	375
62	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. Science, 2012, 337, 1678-1684.	12.6	367
63	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. Science Translational Medicine, 2012, 4, 143ra99.	12.4	367
64	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350, 972-978.	12.6	367
65	Microbiome and Anticancer Immunosurveillance. Cell, 2016, 165, 276-287.	28.9	366
66	Autophagy and Cellular Immune Responses. Immunity, 2013, 39, 211-227.	14.3	359
67	Cancer and the gut microbiota: An unexpected link. Science Translational Medicine, 2015, 7, 271ps1.	12.4	358
68	Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15RÎ±. PLoS ONE, 2009, 4, e4942.	2.5	352
69	Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity. Cancer Research, 2010, 70, 855-858.	0.9	326
70	Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway. Clinical Cancer Research, 2010, 16, 3100-3104.	7.0	325
71	Proteomic Analysis of Exosomes Secreted by Human Mesothelioma Cells. American Journal of Pathology, 2004, 164, 1807-1815.	3.8	318
72	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Frontiers in Immunology, 2015, 6, 588.	4.8	317

#	Article	IF	Citations
73	Targeting PD-1/PD-L1 interactions for cancer immunotherapy. OncoImmunology, 2012, 1, 1223-1225.	4.6	315
74	Nutrition, inflammation and cancer. Nature Immunology, 2017, 18, 843-850.	14.5	313
75	IL-18 Induces PD-1â€“Dependent Immunosuppression in Cancer. Cancer Research, 2011, 71, 5393-5399.	0.9	307
76	Contribution of IL-17â€“producing Î³Î´ T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine, 2011, 208, 491-503.	8.5	303
77	Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. Cancer Research, 2011, 71, 4809-4820.	0.9	302
78	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nature Medicine, 2011, 17, 700-707.	30.7	282
79	Dendritic Cell-Derived Exosomes for Cancer Immunotherapy: What's Next?. Cancer Research, 2010, 70, 1281-1285.	0.9	278
80	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. Cancer Research, 2013, 73, 3499-3510.	0.9	277
81	The IKK complex contributes to the induction of autophagy. EMBO Journal, 2010, 29, 619-631.	7.8	274
82	Immunogenic cancer cell death: a key-lock paradigm. Current Opinion in Immunology, 2008, 20, 504-511.	5.5	271
83	A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Research, 2018, 78, 1003-1016.	0.9	269
84	Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine, 2015, 21, 1128-1138.	30.7	268
85	Mouse models in oncoimmunology. Nature Reviews Cancer, 2016, 16, 759-773.	28.4	267
86	Natural killer cellâ€“directed therapies: moving from unexpected results to successful strategies. Nature Immunology, 2008, 9, 486-494.	14.5	265
87	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in Immunopathology, 2011, 33, 369-383.	6.1	265
88	Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer and Metastasis Reviews, 2011, 30, 61-69.	5.9	250
89	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cellâ€“dependent antitumor effects. Journal of Clinical Investigation, 2004, 114, 379-388.	8.2	248
90	Dendritic and Natural Killer Cells Cooperate in the Control/Switch of Innate Immunity. Journal of Experimental Medicine, 2002, 195, F9-F14.	8.5	240

#	Article	IF	Citations
91	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	4.6	237
92	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunological Reviews, 2006, 214, 229-238.	6.0	235
93	Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection. Journal of Immunology, 2004, 172, 2137-2146.	0.8	233
94	Chemotherapy induces ATP release from tumor cells. Cell Cycle, 2009, 8, 3723-3728.	2.6	233
95	Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity, 2021, 54, 1883-1900.e5.	14.3	233
96	Dendritic Cellâ€“Derived Exosomes as Immunotherapies in the Fight against Cancer. Journal of Immunology, 2014, 193, 1006-1011.	0.8	231
97	The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. European Journal of Immunology, 2015, 45, 17-31.	2.9	229
98	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 315-324.	30.7	225
99	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2014, 3, e957994.	4.6	223
100	Cross-reactivity between tumor MHC class Iâ€“restricted antigens and an enterococcal bacteriophage. Science, 2020, 369, 936-942.	12.6	217
101	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
102	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology, 2017, 6, e1386829.	4.6	209
103	Trial watch. OncoImmunology, 2012, 1, 1323-1343.	4.6	203
104	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Research, 2015, 75, 3800-3811.	0.9	201
105	Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies. Cancer Research, 2008, 68, 4026-4030.	0.9	198
106	Mucosal Imprinting of Vaccine-Induced CD8 ⁺ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Science Translational Medicine, 2013, 5, 172ra20.	12.4	195
107	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. OncoImmunology, 2012, 1, 894-907.	4.6	194
108	Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. Journal of Immunology, 2006, 176, 2722-2729.	0.8	192

#	Article	IF	Citations
109	Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. European Urology, 2020, 78, 195-206.	1.9	192
110	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	12.8	189
111	Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 364-375.	4.9	185
112	Stressâ€“glucocorticoidâ€“TSC22D3 axis compromises therapy-induced antitumor immunity. Nature Medicine, 2019, 25, 1428-1441.	30.7	185
113	Trial Watch. OncoImmunology, 2012, 1, 699-739.	4.6	184
114	Ectoâ€calreticulin in immunogenic chemotherapy. Immunological Reviews, 2007, 220, 22-34.	6.0	183
115	Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Seminars in Immunology, 2010, 22, 113-124.	5.6	183
116	Natural Killer Cell IFN-Î³ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumorâ€Bearing Patients. Cancer Research, 2009, 69, 3563-3569.	0.9	181
117	Apoptosis regulation in tetraploid cancer cells. EMBO Journal, 2006, 25, 2584-2595.	7.8	180
118	Crosstalk between ER stress and immunogenic cell death. Cytokine and Growth Factor Reviews, 2013, 24, 311-318.	7.2	177
119	Trial watch. OncoImmunology, 2013, 2, e24612.	4.6	175
120	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology, 2018, 7, e1526250.	4.6	172
121	eIF2Î± phosphorylation is pathognomonic for immunogenic cell death. Cell Death and Differentiation, 2018, 25, 1375-1393.	11.2	162
122	Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Research, 2019, 29, 846-861.	12.0	160
123	Targeting the gut and tumor microbiota in cancer. Nature Medicine, 2022, 28, 690-703.	30.7	159
124	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nature Medicine, 2022, 28, 535-544.	30.7	158
125	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	4.6	156
126	The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Nonâ€Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 1243-1250.	3.4	154

#	Article	IF	Citations
127	Trial watch. OncoImmunology, 2013, 2, e23510.	4.6	153
128	Trial watch. OncoImmunology, 2012, 1, 1111-1134.	4.6	152
129	Pyroptosis â€“ a cell death modality of its kind?. European Journal of Immunology, 2010, 40, 627-630.	2.9	150
130	Trial watch. OncoImmunology, 2013, 2, e25771.	4.6	150
131	Trial watch: STING agonists in cancer therapy. OncoImmunology, 2020, 9, 1777624.	4.6	148
132	Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. Cancer Research, 2011, 71, 661-665.	0.9	144
133	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research, 2015, 25, 208-224.	12.0	143
134	Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight, 2021, 6, .	5.0	143
135	Cutting Edge: Crucial Role of IL-1 and IL-23 in the Innate IL-17 Response of Peripheral Lymph Node NK1.1â^' Invariant NKT Cells to Bacteria. Journal of Immunology, 2011, 186, 662-666.	0.8	137
136	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. OncoImmunology, 2016, 5, e1149673.	4.6	136
137	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. European Journal of Immunology, 1996, 26, 1335-1341.	2.9	135
138	Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from â€œSilentâ€•to Immunogenic. Cancer Research, 2007, 67, 7941-7944.	0.9	134
139	Trial Watch. OncoImmunology, 2014, 3, e27878.	4.6	134
140	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunology Research, 2016, 4, 895-902.	3.4	134
141	Trial Watch. OncoImmunology, 2013, 2, e25238.	4.6	132
142	Construction and Characterization of Retroviral Vectors Expressing Biologically Active Human Interleukin-12. Human Gene Therapy, 1994, 5, 1493-1506.	2.7	131
143	Immunomodulation by targeted anticancer agents. Cancer Cell, 2021, 39, 310-345.	16.8	131
144	Trial watch. OncoImmunology, 2013, 2, e23082.	4.6	130

#	Article	IF	Citations
145	Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology, 2019, 8, 1638212.	4.6	125
146	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	6.4	122
147	Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506.	4.6	121
148	Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines. Stem Cells, 1997, 15, 94-103.	3.2	120
149	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Science Translational Medicine, 2015, 7, 283ra55.	12.4	120
150	Immunological off-target effects of imatinib. Nature Reviews Clinical Oncology, 2016, 13, 431-446.	27.6	120
151	CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy. Cancer Research, 2014, 74, 436-445.	0.9	118
152	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nature Medicine, 2020, 26, 919-931.	30.7	118
153	Dendritic cell derived-exosomes: biology and clinical implementations. Journal of Leukocyte Biology, 2006, 80, 471-478.	3.3	117
154	Trial watch: TLR3 agonists in cancer therapy. OncoImmunology, 2020, 9, 1771143.	4.6	116
155	Exosome-based immunotherapy. Cancer Immunology, Immunotherapy, 2004, 53, 234-239.	4.2	113
156	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death and Disease, 2021, 12, 258.	6.3	113
157	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. OncoImmunology, 2014, 3, e28473.	4.6	112
158	The breakthrough of the microbiota. Nature Reviews Immunology, 2018, 18, 87-88.	22.7	112
159	Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-Î± Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Research, 2017, 77, 4146-4157.	0.9	107
160	TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer. Cancer Research, 2011, 71, 1607-1614.	0.9	105
161	Immune Response Against Dying Tumor Cells. Advances in Immunology, 2004, 84, 131-179.	2.2	104
162	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. Clinical Cancer Research, 2008, 14, 5242-5249.	7.0	104

#	Article	IF	Citations
163	Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands. Cancer Research, 2010, 70, 490-500.	0.9	104
164	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. OncoImmunology, 2016, 5, e1088631.	4.6	104
165	Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology, 2012, 1, 28-37.	4.6	103
166	Immune responses during COVID-19 infection. OncoImmunology, 2020, 9, 1807836.	4.6	103
167	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e1008814.	4.6	102
168	The immunogenicity of tumor cell death. Current Opinion in Oncology, 2009, 21, 71-76.	2.4	101
169	Trial Watch. OncoImmunology, 2013, 2, e26621.	4.6	101
170	NCR3/NKp30 Contributes to Pathogenesis in Primary SjÃ¶grenâ€™s Syndrome. Science Translational Medicine, 2013, 5, 195ra96.	12.4	99
171	Trial Watch. OncoImmunology, 2014, 3, e27297.	4.6	99
172	The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes, 2019, 10, 424-428.	9.8	98
173	Surfaceâ€exposed calreticulin in the interaction between dying cells and phagocytes. Annals of the New York Academy of Sciences, 2010, 1209, 77-82.	3.8	97
174	Trial Watch: Peptide-based anticancer vaccines. OncoImmunology, 2015, 4, e974411.	4.6	97
175	Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma. Cancer Research, 2014, 74, 7298-7308.	0.9	96
176	The immuno-oncological challenge of COVID-19. Nature Cancer, 2020, 1, 946-964.	13.2	96
177	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. OncoImmunology, 2012, 1, 326-333.	4.6	95
178	Cancer-Induced Immunosuppression: IL-18â€“Elicited Immunoablative NK Cells. Cancer Research, 2012, 72, 2757-2767.	0.9	95
179	Trial Watch:. OncoImmunology, 2014, 3, e28694.	4.6	95
180	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma. Cancer Research, 2004, 64, 2192-2198.	0.9	94

#	Article	IF	Citations
181	Trial watch. OncoImmunology, 2013, 2, e23803.	4.6	92
182	Trial watch. OncoImmunology, 2013, 2, e22789.	4.6	92
183	Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Research, 2016, 76, 4602-4607.	0.9	92
184	Oncolysis without viruses â€" inducing systemic anticancer immune responses with local therapies. Nature Reviews Clinical Oncology, 2020, 17, 49-64.	27.6	92
185	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy, 2015, 11, 1878-1890.	9.1	91
186	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2020, 9, 1777625.	4.6	91
187	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy, 2012, 8, 413-415.	9.1	90
188	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy, 2016, 12, 864-875.	9.1	90
189	Anticancer activity of cardiac glycosides. OncoImmunology, 2012, 1, 1640-1642.	4.6	89
190	Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. OncoImmunology, 2016, 5, e1220467.	4.6	88
191	Trial Watchâ€"Oncolytic viruses and cancer therapy. OncoImmunology, 2016, 5, e1117740.	4.6	88
192	Pro-necrotic molecules impact local immunosurveillance in human breast cancer. OncoImmunology, 2017, 6, e1299302.	4.6	88
193	Trial watch: Dendritic cell-based anticancer immunotherapy. OncoImmunology, 2017, 6, e1328341.	4.6	87
194	PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. British Journal of Cancer, 2019, 120, 3-5.	6.4	87
195	Trial Watch. OncoImmunology, 2012, 1, 493-506.	4.6	86
196	IL-12-Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivo. Annals of the New York Academy of Sciences, 1996, 795, 284-293.	3.8	85
197	Mature Cytotoxic CD56bright/CD16+Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. Cancer Research, 2014, 74, 81-92.	0.9	85
198	STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. Cancer Research, 2015, 75, 3812-3822.	0.9	85

#	Article	IF	Citations
199	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunological Reviews, 2017, 280, 165-174.	6.0	82
200	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. OncoImmunology, 2018, 7, e1462431.	4.6	82
201	Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. Cancer Discovery, 2021, 11, 2396-2412.	9.4	81
202	Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells. Journal of Immunology, 2008, 180, 4679-4686.	0.8	78
203	The dendritic cellâ€“tumor cross-talk in cancer. Current Opinion in Immunology, 2011, 23, 146-152.	5.5	78
204	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. Molecular Cell, 2020, 77, 748-760.e9.	9.7	77
205	Trial Watch. OncoImmunology, 2014, 3, e29179.	4.6	76
206	Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy. Cancer Journal (Sudbury, Mass), 2011, 17, 351-358.	2.0	75
207	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. OncoImmunology, 2013, 2, e24568.	4.6	75
208	Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging, 2021, 13, 6375-6405.	3.1	75
209	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. OncoImmunology, 2014, 3, e27884.	4.6	74
210	How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer and Metastasis Reviews, 2011, 30, 71-82.	5.9	72
211	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	11.2	72
212	Dendritic Cell Maturation Overrules H-2dâ€“Mediated Natural Killer T (Nkt) Cell Inhibition. Journal of Experimental Medicine, 2001, 194, 1179-1186.	8.5	71
213	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	12.8	71
214	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. Journal of Clinical Investigation, 2016, 126, 921-937.	8.2	71
215	Cytokine Gene Therapy of Cancer Using Interleukinâ€12: Murine and Clinical Trials. Annals of the New York Academy of Sciences, 1996, 795, 440-454.	3.8	70
216	Desirable cell death during anticancer chemotherapy. Annals of the New York Academy of Sciences, 2010, 1209, 99-108.	3.8	70

#	Article	IF	Citations
217	Trial Watch. OncoImmunology, 2012, 1, 306-315.	4.6	70
218	Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy, 2012, 8, 1175-1184.	9.1	69
219	Lung cancer: potential targets for immunotherapy. Lancet Respiratory Medicine,the, 2013, 1, 551-563.	10.7	69
220	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. Journal of Molecular Medicine, 2007, 85, 1069-1076.	3.9	68
221	An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy. OncoImmunology, 2014, 3, e944047.	4.6	68
222	IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules. Journal of Immunology, 2004, 172, 5957-5966.	0.8	67
223	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
224	Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 2018, 7, e1503032.	4.6	67
225	Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Molecular Medicine, 2020, 12, e11622.	6.9	67
226	IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts. University of Pittsburgh, Pittsburgh, Pennsylvania. Human Gene Therapy, 1995, 6, 1607-1624.	2.7	66
227	Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells. Journal of Immunology, 2001, 167, 1795-1802.	0.8	65
228	Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunology, Immunotherapy, 2008, 57, 1291-1300.	4.2	65
229	The impact of the intestinal microbiota in therapeutic responses against cancer. Comptes Rendus - Biologies, 2018, 341, 284-289.	0.2	65
230	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	4.6	64
231	Beneficial autoimmunity improves cancer prognosis. Nature Reviews Clinical Oncology, 2021, 18, 591-602.	27.6	63
232	Trial watch: Dendritic cell-based anticancer therapy. OncoImmunology, 2014, 3, e963424.	4.6	62
233	Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. OncoImmunology, 2015, 4, e1058597.	4.6	62
234	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	4.6	62

#	Article	IF	Citations
235	Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade. OncoImmunology, 2019, 8, e1637188.	4.6	61
236	Viral subversion of immunogenic cell death. Cell Cycle, 2009, 8, 860-869.	2.6	60
237	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology, 2017, 6, e1363139.	4.6	60
238	Links between innate and cognate tumor immunity. Current Opinion in Immunology, 2007, 19, 224-231.	5.5	59
239	Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. OncoImmunology, 2012, 1, 393-395.	4.6	58
240	Trial Watch. OncoImmunology, 2013, 2, e24238.	4.6	58
241	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. Frontiers in Immunology, 2018, 9, 2480.	4.8	57
242	Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. European Cytokine Network, 2002, 13, 17-27.	2.0	57
243	Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood, 2002, 100, 2554-2561.	1.4	56
244	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. Journal of Clinical Investigation, 2008, 118, 3751-3761.	8.2	56
245	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. OncoImmunology, 2019, 8, e1657375.	4.6	56
246	Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?. Nature Reviews Immunology, 2020, 20, 522-528.	22.7	54
247	Harnessing dendritic cells in cancer. Seminars in Immunology, 2011, 23, 42-49.	5.6	53
248	Abscopal but desirable. OncoImmunology, 2012, 1, 407-408.	4.6	53
249	Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. OncoImmunology, 2016, 5, e1177692.	4.6	52
250	Trial Watchâ€"Immunostimulation with cytokines in cancer therapy. OncoImmunology, 2016, 5, e1115942.	4.6	52
251	Trial watch: dietary interventions for cancer therapy. OncoImmunology, 2019, 8, e1591878.	4.6	52
252	Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. Journal of Clinical Investigation, 2009, 119, 2127-30.	8.2	51

#	Article	IF	Citations
253	The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. OncoImmunology, 2018, 7, e1434468.	4.6	51
254	Selective Resistance of Tetraploid Cancer Cells against DNA Damage-Induced Apoptosis. Annals of the New York Academy of Sciences, 2006, 1090, 35-49.	3.8	50
255	Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology, 2013, 2, e26494.	4.6	50
256	The ratio of CD8⁺/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. OncoImmunology, 2016, 5, e1218106.	4.6	50
257	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget, 2015, 6, 20840-20850.	1.8	50
258	Dendritic cells and innate defense against tumor cells. Cytokine and Growth Factor Reviews, 2008, 19, 79-92.	7.2	49
259	Trial Watch. OncoImmunology, 2013, 2, e24850.	4.6	49
260	Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions. Journal of Immunology, 2008, 180, 7887-7897.	0.8	47
261	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology, 2015, 4, e985940.	4.6	47
262	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. Cancer Research, 2016, 76, 3122-3126.	0.9	47
263	IKK connects autophagy to major stress pathways. Autophagy, 2010, 6, 189-191.	9.1	46
264	Trial Watchâ€"Small molecules targeting the immunological tumor microenvironment for cancer therapy. OncoImmunology, 2016, 5, e1149674.	4.6	46
265	Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood, 2004, 103, 1966-1967.	1.4	45
266	Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. OncoImmunology, 2016, 5, e1082706.	4.6	45
267	Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. OncoImmunology, 2017, 6, e1132137.	4.6	45
268	The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. Journal of Immunology, 2008, 180, 6477-6483.	0.8	44
269	Cancer Induces a Stress Ileopathy Depending on Î²-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis. Cancer Discovery, 2022, 12, 1128-1151.	9.4	44
270	Victories and deceptions in tumor immunology. OncoImmunology, 2013, 2, e23687.	4.6	43

#	Article	IF	Citations
271	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15RÎ± and NKG2D Triggering. Cancer Research, 2014, 74, 68-80.	0.9	43
272	Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Frontiers in Immunology, 2020, 11, 600886.	4.8	43
273	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy â€" Achieving global consensus and visibility for cellular host-directed therapies. International Journal of Infectious Diseases, 2020, 96, 431-439.	3.3	43
274	The potential of exosomes in immunotherapy. Expert Opinion on Biological Therapy, 2005, 5, 737-747.	3.1	42
275	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. OncoImmunology, 2017, 6, e1137418.	4.6	42
276	The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget, 2015, 6, 26599-26614.	1.8	42
277	Trial Watch: Radioimmunotherapy for oncological indications. OncoImmunology, 2014, 3, e954929.	4.6	40
278	On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. Cell Death and Disease, 2020, 11, 656.	6.3	40
279	Retroviral Vectors for Use in Human Gene Therapy for Cancer, Gaucher Disease, and Arthritis. Annals of the New York Academy of Sciences, 1994, 716, 72-89.	3.8	39
280	Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget, 2015, 6, 11894-11909.	1.8	39
281	BCR/ABL Promotes Dendritic Cellâ€"Mediated Natural Killer Cell Activation. Cancer Research, 2005, 65, 6409-6417.	0.9	38
282	Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle, 2009, 8, 3971-3977.	2.6	38
283	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. OncoImmunology, 2014, 3, e27560.	4.6	38
284	CD103+ Dendritic Cells Producing Interleukin-12 in Anticancer Immunosurveillance. Cancer Cell, 2014, 26, 591-593.	16.8	38
285	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology, 2018, 7, e1433982.	4.6	38
286	The potential of exosomes in immunotherapy of cancer. Blood Cells, Molecules, and Diseases, 2005, 35, 111-115.	1.4	37
287	Identification of pharmacological agents that induce HMGB1 release. Scientific Reports, 2017, 7, 14915.	3.3	37
288	Loss-of-function alleles ofP2RX7andTLR4fail to affect the response to chemotherapy in non-small cell lung cancer. OncoImmunology, 2012, 1, 271-278.	4.6	36

#	Article	IF	Citations
289	Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab. Cancer Research, 2013, 73, 4663-4673.	0.9	36
290	Trial Watch. OncoImmunology, 2014, 3, e28185.	4.6	36
291	Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity. Antioxidants and Redox Signaling, 2014, 20, 1098-1116.	5.4	36
292	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology, 2017, 6, e1371896.	4.6	36
293	Killer dendritic cells: IKDC and the others. Current Opinion in Immunology, 2008, 20, 558-565.	5.5	35
294	Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy. OncoImmunology, 2014, 3, e27663.	4.6	35
295	Subversion of anticancer immunosurveillance by radiotherapy. Nature Immunology, 2015, 16, 1005-1007.	14.5	35
296	Murine Models of Cancer Cytokine Gene Therapy Using Interleukin-12. Annals of the New York Academy of Sciences, 1996, 795, 275-283.	3.8	34
297	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. Biology of Blood and Marrow Transplantation, 2010, 16, 709-728.	2.0	34
298	Cutting Edge: FcÎ³RIII (CD16) and FcÎ³RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. Journal of Immunology, 2012, 189, 5513-5517.	0.8	34
299	Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells: Figure 1.. Cancer Research, 2007, 67, 851-853.	0.9	33
300	Interleukin-12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long-term Antitumor Immunity in Syngeneic C3H Mice. Laryngoscope, 1998, 108, 261-268.	2.0	32
301	Anticancer effects of anti-CD47 immunotherapy in vivo. OncoImmunology, 2019, 8, 1550619.	4.6	32
302	CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancerâ€“Draining Lymph Nodes. Cancer Immunology Research, 2019, 7, 208-218.	3.4	32
303	Trial Watch. OncoImmunology, 2014, 3, e28344.	4.6	31
304	Microbiota Modulation of Myeloid Cells in Cancer Therapy. Cancer Immunology Research, 2015, 3, 103-109.	3.4	31
305	Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. OncoImmunology, 2015, 4, e1042202.	4.6	31
306	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death and Differentiation, 2021, 28, 3297-3315.	11.2	31

#	Article	IF	Citations
307	The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle, 2015, 14, 3506-3512.	2.6	30
308	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. OncoImmunology, 2017, 6, e1163456.	4.6	30
309	Trial watch: DNA-based vaccines for oncological indications. OncoImmunology, 2017, 6, e1398878.	4.6	30
310	Phase I clinical trial combining imatinib mesylate and IL-2. OncoImmunology, 2013, 2, e23080.	4.6	29
311	Antibodies regulate antitumour immunity. Nature, 2015, 521, 35-37.	27.8	29
312	Trial Watch: Adoptive cell transfer for oncological indications. OncoImmunology, 2015, 4, e1046673.	4.6	29
313	Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer. OncoImmunology, 2020, 9, 1795995.	4.6	29
314	Interferon-Î³ induces cancer cell ferroptosis. Cell Research, 2019, 29, 692-693.	12.0	28
315	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Cancer Discovery, 2021, 11, 408-423.	9.4	28
316	Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2017, 35, 462-462.	1.6	28
317	Integration of Host-Related Signatures with Cancer Cellâ€“Derived Predictors for the Optimal Management of Anticancer Chemotherapy. Cancer Research, 2010, 70, 9538-9543.	0.9	27
318	Natural killer cells in non-hematopoietic malignancies. Frontiers in Immunology, 2012, 3, 395.	4.8	27
319	Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress. OncoImmunology, 2014, 3, e28276.	4.6	27
320	A p53-regulated immune checkpoint relevant to cancer. Science, 2015, 349, 476-477.	12.6	27
321	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology, 2016, 136, 994-1001.	0.7	27
322	Contribution of annexin A1 to anticancer immunosurveillance. OncoImmunology, 2019, 8, e1647760.	4.6	27
323	Immune checkpoint inhibitors. Journal of Experimental Medicine, 2021, 218, .	8.5	27
324	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. OncoImmunology, 2015, 4, e988042.	4.6	27

#	Article	IF	Citations
325	The Dendritic Cellâ€“like Functions of IFN-Producing Killer Dendritic Cells Reside in the CD11b+ Subset and Are Licensed by Tumor Cells. Cancer Research, 2009, 69, 6590-6597.	0.9	26
326	Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.	4.6	26
327	TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. OncoImmunology, 2018, 7, e1386826.	4.6	26
328	Tumor lysis with LTX-401 creates anticancer immunity. OncoImmunology, 2019, 8, e1594555.	4.6	26
329	The oncolytic compound LTX-401 targets the Golgi apparatus. Cell Death and Differentiation, 2016, 23, 2031-2041.	11.2	25
330	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. OncoImmunology, 2019, 8, e1498285.	4.6	25
331	PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. OncoImmunology, 2022, 11, .	4.6	25
332	Interferon-Î³ is produced by another player of innate immune responses: The interferon-producing killer dendritic cell (IKDC). Biochimie, 2007, 89, 872-877.	2.6	24
333	Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. OncoImmunology, 2018, 7, e1484980.	4.6	24
334	Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals. Cell Cycle, 2009, 8, 639-642.	2.6	23
335	Anticancer effects of imatinib via immunostimulation. Nature Medicine, 2011, 17, 1050-1051.	30.7	23
336	OncoImmunology: a new journal at the frontier between oncology and immunology. OncoImmunology, 2012, 1, 1-2.	4.6	23
337	Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. OncoImmunology, 2013, 2, e24786.	4.6	23
338	Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. , 2022, 10, e004191.		23
339	Can the exome and the immunome converge on the design of efficient cancer vaccines?. OncoImmunology, 2012, 1, 579-580.	4.6	22
340	Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. OncoImmunology, 2013, 2, e23472.	4.6	22
341	Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. Seminars in Oncology, 2015, 42, 448-458.	2.2	22
342	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. OncoImmunology, 2020, 9, 1774298.	4.6	22

#	Article	IF	Citations
343	Following up tumor-specific regulatory T cells in cancer patients. OncoImmunology, 2013, 2, e25444.	4.6	21
344	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. OncoImmunology, 2016, 5, e1139275.	4.6	21
345	From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. Current Opinion in Molecular Therapeutics, 2002, 4, 372-81.	2.8	21
346	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. OncoImmunology, 2013, 2, e22409.	4.6	20
347	NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. OncoImmunology, 2016, 5, e1154251.	4.6	20
348	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. OncoImmunology, 2017, 6, e1299303.	4.6	20
349	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. Cell Death and Disease, 2018, 9, 1086.	6.3	20
350	Cross-reactivity between cancer and microbial antigens. OncoImmunology, 2021, 10, 1877416.	4.6	20
351	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. Journal of Experimental Medicine, 2021, 218, .	8.5	20
352	In vivo veritas. Nature Biotechnology, 2005, 23, 1372-1374.	17.5	19
353	Therapy-induced microenvironmental changes in cancer. Journal of Molecular Medicine, 2016, 94, 497-508.	3.9	19
354	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. OncoImmunology, 2013, 2, e23079.	4.6	18
355	Multifaceted modes of action of the anticancer probiotic Enterococcus hirae. Cell Death and Differentiation, 2021, 28, 2276-2295.	11.2	18
356	Death, danger, and immunity: an infernal trio. Immunological Reviews, 2007, 220, 5-7.	6.0	17
357	Homeostatic defects in interleukin 18â€deficient mice contribute to protection against the lethal effects of endotoxin. Immunology and Cell Biology, 2011, 89, 739-746.	2.3	17
358	Immunological effects of chemotherapy in spontaneous breast cancers. OncoImmunology, 2013, 2, e27158.	4.6	17
359	Why should we need the gut microbiota to respond to cancer therapies?. OncoImmunology, 2014, 3, e27574.	4.6	17
360	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib. Cancer Immunology Research, 2017, 5, 582-593.	3.4	17

#	Article	IF	Citations
361	Immunostimulatory gut bacteria. Science, 2019, 366, 1077-1078.	12.6	17
362	Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.. Journal of Clinical Oncology, 2020, 38, 3095-3095.	1.6	17
363	CD4+ T Cells at the Center of Inflammaging. Cell Metabolism, 2020, 32, 4-5.	16.2	16
364	Title is missing!. Annals of Oncology, 2000, 11, 199-206.	1.2	16
365	Cross-reactivity between microbial and tumor antigens. Current Opinion in Immunology, 2022, 75, 102171.	5.5	16
366	Improvement of immunogenic chemotherapy by STAT3 inhibition. OncoImmunology, 2016, 5, e1078061.	4.6	15
367	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. PLoS ONE, 2015, 10, e0133363.	2.5	14
368	Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. OncoImmunology, 2016, 5, e1118600.	4.6	14
369	Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. OncoImmunology, 2016, 5, e1064581.	4.6	14
370	Inosine: novel microbiota-derived immunostimulatory metabolite. Cell Research, 2020, 30, 942-943.	12.0	14
371	Bacterial Invasion: Linking Autophagy and Innate Immunity. Current Biology, 2010, 20, R106-R108.	3.9	13
372	Targeting dendritic cell metabolism in cancer. Nature Medicine, 2010, 16, 858-859.	30.7	13
373	Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. Cell Death and Disease, 2021, 12, 599.	6.3	13
374	IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. European Journal of Immunology, 2005, 35, 2840-2850.	2.9	12
375	Introduction: the immune response against dying cells. Current Opinion in Immunology, 2008, 20, 501-503.	5.5	12
376	IKDCs or B220+ NK cells are pre-mNK cells. Blood, 2012, 119, 4345-4346.	1.4	12
377	STAT3 inhibition for cancer therapy: Cell-autonomous effects only?. OncoImmunology, 2016, 5, e1126063.	4.6	12
378	A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. OncoImmunology, 2019, 8, 1606665.	4.6	12

#	Article	IF	Citations
379	Lower Airway Dysbiosis Exacerbates Lung Cancer. Cancer Discovery, 2021, 11, 224-226.	9.4	12
380	Witch Hunt against Tumor Cells Enhanced by Dendritic Cells. Annals of the New York Academy of Sciences, 2009, 1174, 51-60.	3.8	11
381	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. OncoImmunology, 2016, 5, e1160193.	4.6	11
382	Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. Cell Death and Differentiation, 2021, 28, 1532-1547.	11.2	11
383	Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 405-407.	5.0	11
384	Impact of the ileal microbiota on colon cancer. Seminars in Cancer Biology, 2022, 86, 955-966.	9.6	11
385	Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. Cancer Genomics and Proteomics, 2007, 4, 65-70.	2.0	11
386	An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae. Cell Cycle, 2011, 10, 118-126.	2.6	10
387	Positive impact of autophagy in human breast cancer cells on local immunosurveillance. OncoImmunology, 2016, 5, e1174801.	4.6	10
388	Differences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based meta-analysis. OncoImmunology, 2016, 5, e1067746.	4.6	10
389	A genotype-phenotype screening system using conditionally immortalized immature dendritic cells. STAR Protocols, 2021, 2, 100732.	1.2	10
390	Harnessing the microbiome to restore immunotherapy response. Nature Cancer, 2021, 2, 1301-1304.	13.2	10
391	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	4.8	9
392	Failure of immunosurveillance accelerates aging. OncoImmunology, 2019, 8, e1575117.	4.6	9
393	Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients. Aging, 2021, 13, 20860-20885.	3.1	9
394	Immunodynamics of explanted human tumors for immunoâ€oncology. EMBO Molecular Medicine, 2021, 13, e12850.	6.9	9
395	Immune infiltrate in cancer. Aging, 2015, 7, 358-359.	3.1	9
396	Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology, 2022, 11, .	4.6	9

#	Article	IF	Citations
397	Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nature Medicine, 2012, 18, 346-346.	30.7	8
398	Prime time for immune-checkpoint targeted therapy at ASCO 2015. OncoImmunology, 2016, 5, e1068494.	4.6	8
399	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. OncoImmunology, 2020, 9, 1677427.	4.6	8
400	Boosting the immunotherapy response by nutritional interventions. Journal of Clinical Investigation, 2022, 132, .	8.2	8
401	Pegylated Engineered IL2 plus Antiâ€“PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. Cancer Discovery, 2020, 10, 1097-1099.	9.4	7
402	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. OncoImmunology, 2020, 9, 1794423.	4.6	7
403	COVID-19: a challenge for oncology services. OncoImmunology, 2020, 9, 1760686.	4.6	7
404	Seeking Cellular Fitness and Immune Evasion: Autophagy in Pancreatic Carcinoma. Cancer Cell, 2020, 37, 759-760.	16.8	7
405	Subversion of calreticulin exposure as a strategy of immune escape. Cancer Cell, 2021, 39, 449-451.	16.8	7
406	The Porto European Cancer Research Summit 2021. Molecular Oncology, 2021, 15, 2507-2543.	4.6	7
407	Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics. Cell Metabolism, 2022, 34, 350-352.	16.2	7
408	Cytokines reinstate NK cellâ€“mediated cancer immunosurveillance. Journal of Clinical Investigation, 2014, 124, 4687-4689.	8.2	6
409	The complement system is also important in immunogenic cell death. Nature Reviews Immunology, 2017, 17, 143-143.	22.7	6
410	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. Cell Cycle, 2010, 9, 2902-2907.	2.6	5
411	Recent successes of cancer immunotherapy: a new dimension in personalized medicine?. Targeted Oncology, 2012, 7, 1-2.	3.6	5
412	A probiotic supplement boosts response to cancer immunotherapy. Nature Medicine, 2022, 28, 633-634.	30.7	5
413	Leptin-Producing Oncolytic Virus Makes Tumor-Infiltrating T Cells Fit, Not Fat. Immunity, 2019, 51, 423-425.	14.3	4
414	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. OncoImmunology, 2019, 8, e1660121.	4.6	4

#	Article	IF	Citations
415	Antibiotics impair immunotherapy for urothelial cancer. Nature Reviews Urology, 2020, 17, 605-606.	3.8	4
416	Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. OncoImmunology, 2020, 9, 1789284.	4.6	4
417	Targeting Foxp1 for Reinstating Anticancer Immunosurveillance. Immunity, 2014, 41, 345-347.	14.3	3
418	Reply to â€˜Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanomaâ€™. Nature Communications, 2018, 9, 2922.	12.8	3
419	Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?. Signal Transduction and Targeted Therapy, 2021, 6, 178.	17.1	3
420	Antibody co-targeting of DCs. Blood, 2011, 118, 6726-6727.	1.4	2
421	Unchaining NK cellâ€“mediated anticancer immunosurveillance. Nature Immunology, 2016, 17, 746-747.	14.5	1
422	Turning tolerogenic into immunogenic ileal cell death through ileal microbiota: the key to unlock the mystery of colon cancer immunoscore?. OncoImmunology, 2020, 9, 1778834.	4.6	1
423	Commensals shape the immune system. Nature Reviews Immunology, 2021, 21, 615-615.	22.7	1
424	IL-18 Elicited Suppressor NK Cells with Immunoregulatory Functions. Blood, 2008, 112, 106-106.	1.4	1
425	The dialogue between natural killer cells and dendritic cells. International Congress Series, 2005, 1285, 169-176.	0.2	0
426	Personalized immunotherapy: a siren myth?. Personalized Medicine, 2009, 6, 469-473.	1.5	0
427	The European Academy of Tumor Immunology: Bridging fields, continents and generations. OncoImmunology, 2012, 1, 127-128.	4.6	0
428	Correction: Cutting Edge: FcÎ³RIII (CD16) and FcÎ³RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. Journal of Immunology, 2013, 190, 1381-1381.	0.8	0
429	Anticorps monoclonaux en oncologie : dÃ©clencher une rÃ©ponse immunitaire en plus de la rÃ©duction tumorale spÃ©cifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0